fasudil and Angina Pectoris with Normal Coronary Arteriogram studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Research Excerpts

Excerpt	Relevance	Reference
"We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm."	9.10	Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003)
"We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm."	5.10	Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003)

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trials

1 trial available for fasudil and Angina Pectoris with Normal Coronary Arteriogram

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232]				32 participants (Actual)	Interventional	2015-07-07	Terminated (stopped due to Lack of Accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]